-+ 0.00%
-+ 0.00%
-+ 0.00%

Biodesix Targets 2028 Launch for Imaging-Based Lung Nodule Risk Test

PUBT·10/19/2026 10:03:35
Listen to the news
Biodesix Targets 2028 Launch for Imaging-Based Lung Nodule Risk Test
  • Biodesix added digital diagnostics to its lung testing strategy, targeting a 2028 commercial launch for its first imaging-based lung nodule risk test.
  • Developed with Vanderbilt University and Vanderbilt Health, the test aims to improve lung cancer risk assessment alongside the Nodify Lung blood-testing portfolio.
  • Initial performance results will be presented at the RSNA annual meeting on December 3, 2026.
  • The prospective STRATIFY study is expected to begin in the fourth quarter of 2026, matching blood and imaging biomarkers with clinical outcomes.
  • The study will support clinical validation, reimbursement evidence and future multimodal diagnostic development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodesix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190600PRIMZONEFULLFEED9848106) on October 19, 2026, and is solely responsible for the information contained therein.